United States News All stories

Brown-Forman (NYSE:BFA) today reported financial results for its fourth quarter and full fiscal year ended April 30, 2026.

Mobix Labs (NASDAQ:MOBX) announced today that it has entered into a binding Letter of Intent (LOI) to acquire Vision Aerial, a Montana-based manufacturer of high-end unmanned aerial systems (UAS).

Biogen (NASDAQ:BIIB) announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to its investigational antisense oligonucleotide, salanersen, for the treatment of spinal muscular atrophy (SMA).

Fractyl Health (NASDAQ:GUTS) today announced positive one-year, open-label results from its REVEAL-1 study, which evaluated the Revita® duodenal mucosal resurfacing procedure in patients who had discontinued the use of GLP-1 receptor agonist medications.

Gogo (NASDAQ:GOGO) announced today that its military and government subsidiary, SD Government, has secured a multi-year blanket purchase agreement with the National Oceanic and Atmospheric Administration (NOAA).

LeonaBio (NASDAQ:LONA) announced today that Chief Medical Officer Javier San Martin, MD, presented the company’s clinical strategy for its lead ALS candidate, brelgometon (ATH-1105), at the 5th Annual ALS Drug Development Summit in Boston.

Orion Energy Systems (NASDAQ:OESX) reported financial results for its fiscal year 2026 today, detailing a period of ongoing investment and operational transition.

AN2 Therapeutics (NASDAQ:ANTX) announced positive data today from two separate studies evaluating its investigational oral CPSF3 inhibitor, AN2-502998, for the treatment of chronic Chagas disease—a parasitic condition caused by Trypanosoma cruzi that affects millions globally.

Click Holdings (NASDAQ:CLIK), a Hong Kong-based provider of human resources and senior care solutions, reported strong operational growth for the third quarter of its 2025/26 financial year, covering the period from January to March 2026.

TKO Group Holdings (NYSE:TKO) announced today that its board of directors has declared a quarterly cash dividend.

Teledyne Technologies (NYSE:TDY) announced today that its subsidiary, Teledyne FLIR Defense, has been awarded an $11.2 million contract by the U.S. Army’s Capability Program Executive for Chemical, Biological, Radiological and Nuclear Defense (CPE CBRND).

Ciena (NYSE:CIEN) reported robust financial results for its fiscal second quarter ended May 2, 2026, showcasing the impact of escalating global demand for high-speed connectivity solutions.

The Buckle (NYSE:BKE) reported positive sales figures for the four-week fiscal month ended May 30, 2026, marking a continued period of growth for the retailer.

Caleres (NYSE:CAL), a portfolio of consumer-driven footwear brands, reported financial results for the first quarter of 2026 today, highlighted by a significant performance gap between its wholesale brand operations and its retail footprint.

Bio-Techne (NASDAQ:TECH) and Refeyn have launched a new integrated analytical workflow designed to streamline the characterization of complex biologics.

Columbus McKinnon (NASDAQ:CMCO) reported its financial results for the fourth quarter and full fiscal year 2026 today, highlighting the substantial impact of its recent Kito Crosby acquisition.

MarketAxess Holdings (NASDAQ:MKTX) saw a broad rebound in trading volumes across most product categories during May 2026, recovering from levels recorded in April.

Somnigroup International (NYSE:SGI) announced today that its proposed acquisition of Leggett & Platt (NYSE:LEG) has cleared a significant regulatory hurdle.

X-energy (NASDAQ:XE) reported total revenues and grant income of $43.4 million for the first quarter of 2026, marking a 109% increase compared to the same period in 2025.

Alvotech (NASDAQ:ALVO) has officially resubmitted its Biologics License Applications (BLAs) to the U.S. Food and Drug Administration (FDA) for two of its lead biosimilar candidates: AVT05, a proposed biosimilar to Simponi and Simponi Aria (golimumab), and AVT06, a proposed biosimilar to Eylea (aflibercept) 2 mg.

111 (NASDAQ:YI) reported unaudited financial results for the first quarter of 2026 today, signaling the company's deepening transition toward a more lean and technology-oriented operating structure.

Biogen (NASDAQ:BIIB) and UCB have announced the release of positive results from the Phase 3 PHOENYCS GO clinical trial evaluating dapirolizumab pegol (DZP), an investigational treatment for systemic lupus erythematosus (SLE).

Pharming Group (NASDAQ:PHAR) announced today that the U.S. Food and Drug Administration (FDA) has accepted its resubmitted supplemental New Drug Application (sNDA) for Joenja (leniolisib).

GloBra’s patent covering the Chain Code Technology and Parallel Token Solution used in GLBrain and GLMall has finally been approved by both the European and United States patent offices.

The grants are registered under European Patent EP 3 857 405 B1 and US Patent 12,430,644.